$KDS (+59% intraday) Kiadis announced the exclusive license of preclinical natural killer #CellTherapy assets to Sanofi. $SNY

Kiadis to receive €17.5M upfront + up to €857.5M in milestones.

Relevant to NK players: $FATE $JNJ $TAK $NK $GILD $KITE $EDIT

https://t.co/c9FpFS4bbz